Novo Nordisk’s GLP-1 Victoza (liraglutude) received FDA approval for three new indications on Aug. 25, 2017. In addition to being used to treat type 2 diabetes, the drug can now be prescribed to reduce the risk of heart attack, stroke and cardiovascular death to diabetes patients with a history of cardiovascular disease. It is the first diabetes drug authorized by the FDA to also treat cardiovascular conditions.
This is a significant development for diabetes patients as the condition increases cardiovascular risk. In Mexico, cardiovascular disease and diabetes held the top two spots as causes of death in 2015, responsible for almost 130,000 and around 100,000 deaths, respectively.
Victoza was originally approved by the FDA on Jan. 25, 2010 to improve glycemic control in adults with T2D. In September 2010, the LEADER trials began to test for cardiovascular indications and results were published in the New England Journal of Medicine in 2016. The drug has been available in Mexico since Sep. 24, 2015 under the name Saxenda and is currently authorized only for its diabetic indication.